YQYuanqian Qu

Yuanqian Qu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuanqian Qu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Miao-Miao Niu

    Department of Gastroenterology, The First People’s Hospital of Kunshan, Suzhou, China

    2 shared publications
  • Yang Zhou

    Department of Pathology, The Second People’s Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Changzhou, China

    2 shared publications
  • Hai Zhang

    Department of Hepatobiliary Surgery, The Affiliated Hospital of Jiangsu University, Zhenjiang, China

    1 shared publication
  • Jindong Li

    Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China

    1 shared publication
  • Qinghua Wang

    Department of Gastroenterology, The First People’s Hospital of Kunshan, Suzhou, China

    1 shared publication
  • Shutong Chen

    Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China

    1 shared publication

Latest Publications

  • Open Access

    Identification of novel and potent dual-targeting HDAC1/SPOP inhibitors using structure-based virtual screening, molecular dynamics simulation and evaluation of in vitro and in vivo antitumor activity

    by Yingxue Yang, Shutong Chen, Qinghua Wang, Miao-Miao Niu, Yuanqian Qu, Yang Zhou

    Cancer is one of the important factors threatening human health. Hence, it is essential to create novel potent drugs to treat it. Due to the strong correlation among histone deacetylase1 (HDAC1), speckle-type POZ protein (SPOP) and cancers, dual inhibition of HDAC1 and SPOP may be a promising strategy for cancer treatment. In this study, we successfully identified four potential dual-targeting HDAC1/SPOP candidate compounds with structure-based virtual screening. In vitro inhibition experiments confirmed that the four compounds had dual inhibitory effects on HDAC1 and SPOP. Among them, compound HS-2 had a stronger inhibitory effect on HDAC1 and SPOP than the positive controls. Further molecular dynamics simulations indicated that HS-2 could stably bind to HDAC1 and SPOP. In addition, MTT assay indicated that HS-2 inhibited the growth of tumor cells in the micromolar range. In vivo evaluation showed that HS-2 could obviously inhibit the growth of tumor in nude mice without obvious toxicity. These findings suggest that HS-2 is a novel and potent dual-targeting HDAC1/SPOP inhibitor for cancer treatment.


  • Open Access

    Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation

    by Yuting Wang, Hai Zhang, Jindong Li, Miao-Miao Niu, Yang Zhou, Yuanqian Qu

    KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of pancreatic cancer. Herein, we identified four potent and noncovalent KRASG12D inhibitors (hits 1–4) by using structure-based virtual screening and biological evaluation. The in vitro assays indicated that the four compounds had sub-nanomolar affinities for KRASG12D and showed a dose-dependent inhibitory effect on human pancreatic cancer cells. In particular, the hit compound 3 was the most promising candidate and significantly inhibited the tumor growth of pancreatic cancer in tumor-bearing mice. The hit compound 3 represented a promising starting point for structural optimization in hit-to-lead development. This study shows that hit compound 3 provides a basis for the development of the treatment of cancer driven by KRASG12D.